...
首页> 外文期刊>OncoTargets and therapy >Construction and Analysis of a Long Non-Coding RNA-Associated Competing Endogenous RNA Network Identified Potential Prognostic Biomarkers in Luminal Breast Cancer
【24h】

Construction and Analysis of a Long Non-Coding RNA-Associated Competing Endogenous RNA Network Identified Potential Prognostic Biomarkers in Luminal Breast Cancer

机译:长期非编码RNA相关竞争内源性RNA网络的构建与分析鉴定了腔乳腺癌中的潜在预后生物标志物

获取原文
           

摘要

Purpose: To construct a competing endogenous RNA (ceRNA) topology network of RNA-seq data and micro RNA-seq (miRNA-seq) data to identify key prognostic long non-coding RNA (lncRNAs) in luminal breast cancer, and validate the results by human luminal breast cancer samples. Materials and Methods: The RNA-seq data and miRNA-seq data of luminal A breast cancer in the The Cancer Genome Atlas (TCGA) database were downloaded and compared with those in the miRcode database to obtain lncRNA–miRNA relationship pairs. Final target genes were predicted by all three databases (miRDB, miRTarBase, and TargetScan), thereby obtaining the miRNA-messenger RNA (miRNA-mRNA) relationship pairs and a ceRNA topology network was constructed, then mRNA enrichment analysis, ceRNA topological and stability analysis, univariate and multivariate Cox regression analysis were performed. Overall survival (OS) was evaluated and the key prognostic RNAs were identified. The expression difference between normal and tumor, as well as the correlation of high expression in tumor with pathological parameters (Ki-67, Grade, tumor diameter) were validated by human breast cancer specimens. Results: A ceRNA topology network was constructed and six lncRNAs were finally identified (The higher expression of PART1, IGF2.AS, WT1.AS, OIP5.AS1, and SLC25A5.AS1 was associated with poor prognosis while AL035706.1 was adverse) and the poor prognostic ones were higher expressed in tumor tissue and correlated with a higher Ki-67 ( 10%), tumor grades (II, III) and tumor diameters ( 1.5 cm). Using six lncRNAs, we constructed a prognostic model, which performed well for the classification of prognosis in the module. Conclusion: We identified and verified six biomarkers (OS-predicting) in luminal breast cancer, which significantly enriched the prediction and potential targets of this subtype.
机译:目的:构建RNA-SEQ数据和微RNA-SEQ(MiRNA-SEQ(MiRNA-SEQ)数据的竞争内源性RNA(CERNA)拓扑网络,以识别腔乳腺癌中的关键预后长期非编码RNA(LNCRNA),并验证结果通过人类腔乳腺癌样品。材料和方法:下载癌症基因组Atlas(TCGA)数据库中腔乳腺癌的RNA-SEQ数据和MiRNA-SEQ数据,并与MiRcode数据库中的那些进行比较,以获得LNCRNA-miRNA关系对。所有三个数据库(MIRDB,MIRRARBase和TargetScan)预测最终的靶基因,从而获得MiRNA-Messenger RNA(miRNA-mRNA)关系对和Cerna拓扑网络被构建,然后MRNA富集分析,Cerna拓扑和稳定性分析,进行单变量和多变量COX回归分析。评估总存活(OS)并确定关键的预后RNA。通过人乳腺癌标本验证正常和肿瘤之间的表达差异,以及具有病理参数(KI-67,级,肿瘤直径)的肿瘤中的高表达的相关性。结果:构建了Cerna拓扑网络,最终鉴定了六个LNCRNA(part1,IgF2.as,wt1.as,OIP5.as1和SLC25A5.as1的较高表达与预后差,而AL035706.1是不利的,而且较差的预后较高的肿瘤组织表达,并与较高的Ki-67(> 10%),肿瘤等级(III)和肿瘤直径(> 1.5cm)相关。使用六个LNCRNA,我们构建了一种预后模型,这对模块预后的分类进行了良好。结论:我们在腔乳腺癌中鉴定并验证了六个生物标志物(OS预测),这显着富集了该亚型的预测和潜在靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号